vedolizumab sold brand name entyvio monoclonal antibody medication developed millennium pharmaceuticals inc treatment ulcerative colitis crohns binds integrin lymphocyte peyers patch adhesion molecule dimer integrin integrin blocking integrin results gutselective antiinflammatory vedolizumab approved use adults moderate severe ulcerative colitis crohns disease poor response tumor necrosis factor tnf blockers corticosteroids vedolizumab may used treat steroid refractory checkpoint inhibitor induced colitis infliximab ineffective vedolizumab investigated several studies adult patients moderate severe active disease conventional therapy tnfalpha antagonists ineffective could tolerated received either vedolizumab placebo main measure effectiveness proportion patients whose symptoms improved six weeks treatment vedolizumab shown effective placebo patients received vedolizumab showed improvement symptoms compared patients received placebo study also showed vedolizumab maintained effect weeks effectively verification moreover vedolizumab treatment shown achieve higher percentage clinical remissions vs patients ulcerative colitis comparison adalimumab one main study adult patients moderate severe active crohns disease conventional therapy tnfalpha antagonists ineffective could tolerated vedolizumab shown effective placebo patients receiving vedolizumab showed improved symptoms weeks treatment compared patients placebo maintenance effect weeks effective vedolizumab cell line used develop vedolizumab created physician scientists massachusetts general hospital boston result work executed dr robert colvins lab part program analyze molecular basis lymphocyte antibody isolated reacted long term activated antigenspecific tetanus toxoid tlymphocytes originally isolated blood lymphocytes cell lines created dr jim kurnicks lab although antibody block primary activation tlymphocytes appeared late activation number lymphocytic stimuli named first activation marker identified group investigators dr andrew lazarovits postdoctoral fellow laboratory discovered murine homologue chiefly published original key papers late coordinated led studies development application crohns disease ulcerative colitis dr lynn bairds group showed antibody reacted single protein band dr atul bhans group showed stained tissue lymphocytes react nonlymphoid tissues although limited efficacy ability prevent kidney rejection subhuman primate transplantation model dr lazarovits continued investigate activities returned canada become director transplantation university western later determined monoclonal antibody reacted integrin subsequently shown interact gutassociated addressin madcam early work dr bruce yacyshyn showed differential expression inflammatory bowel dr lazarovits isolated antibody produce murine homologue licensed massachusetts general hospital millennium pharmaceuticals boston scientists leukosite realized potential antibody treat inflammatory bowel disease company eventually acquired millennium took exclusive license cell line massachusetts general hospital vivo proof concept ultimately led decision humanize antibody move clinical trials vedolizumab addition reactivity gutassociated lymphoid tissues antibody also stains large numbers lymphocytes rheumatoid synovium shown dr ansari emory university prevent delay onset aids monkeymodel simian immunodeficiency virusinduced aids thus reactivity antibody may show widespread applicability inflammatory processes diverse etiologies takeda filed marketing authorization application maa european union march biologic license application bla us food drug administration june crohns disease ulcerative september vedolizumab given priority review status functions expedite potential acceptance march committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization vedolizumab brand name may vedolizumab entyvio approved fda treatment moderatetosevere ulcerative colitis moderatetosevere crohns may entyvio approved medical use european union april health canada approved vedolizumab eventually completed number phase iii clinical crohns disease ulcerative colitis gemini gemini gemini demonstrate vedolizumab effective well tolerated results gemini gemini randomized placebo controlled multicenter trials induction maintenance therapy crohns disease ulcerative colitis additional clinical trial gemini lts longterm safety still october scientists emory university national institute allergy infectious diseases niaid published paper claimed applied daily art antiretroviral therapy days followed simianized rhesus macaques anti antibody siv rhesus macaques weeks twenty three months stopping art antibody treatment vivo siv level still remained undetectable therefore treating hiv people art simultaneously may new therapy could potentially lead hiv infection mice vedolizumab able prevent control phase clinical trial therapy initialized niaid since may participants get vedolizumab infusions every four weeks weeks week vedolizumab infusions cart combination art kept weeks blood draws repeated baseline tests stopped viral load count monitored biweekly hiv viral load goes high cell counts decrease much vedolizumab used alone cart brought back published results clinical trial suggest blockade may effective strategy inducing virological remission hivinfected individuals art interruption one patient showed prolonged virus immune activation dostarlimab ibalizumab httpsenwikipediaorgwikivedolizumab